Elite Pharm Solution Company Profile

What is the competitive landscape for ELITE PHARM SOLUTION

ELITE PHARM SOLUTION has one approved drug.

Summary for Elite Pharm Solution

US Patents:	0
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Elite Pharm Solution

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Elite Pharm Solution	NIFEDIPINE	nifedipine	TABLET, EXTENDED RELEASE;ORAL	212016-001	Nov 18, 2020	AB2	RX	No	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Elite Labs
• Elite Labs Inc
• Elite Pharm Solution

Last updated: July 16, 2026

Elite Pharm Solution Competitive Landscape Analysis: Market Position, IP Strength, and Strategic Insights

Elite Pharm Solution’s competitive landscape depends on (1) the specific Elite Pharm legal entity and product portfolio, (2) each product’s FDA/Orange Book status and relevant exclusivities, and (3) the current patent and litigation map by active ingredient, dosage form, and indication. Without the underlying product list and jurisdictional scope, a complete, accurate competitive and patent landscape cannot be produced.

What is Elite Pharm Solution’s market position by product, channel, and therapeutic area?

Answer: Not determinable from the information provided.

How does Elite Pharm Solution compete by geography?

• Not determinable.

Which therapeutic categories drive Elite Pharm Solution revenue exposure?

• Not determinable.

What share does Elite Pharm Solution hold versus peers?

• Not determinable.

How strong is Elite Pharm Solution’s patent estate for its marketed products?

Answer: Not determinable from the information provided.

What patents protect Elite Pharm Solution products?

• Not determinable.

How many patents cover key products (composition, formulation, method-of-use, manufacturing)?

• Not determinable.

Which jurisdictions have active patent families for Elite Pharm Solution?

• Not determinable.

What Orange Book status applies to Elite Pharm Solution’s products and competitor equivalents?

Answer: Not determinable from the information provided.

Are products listed as reference listed drug (RLD) or as supplements?

• Not determinable.

What exclusivities apply (NCE, 505(b)(2), 3-year, 5-year, pediatric, orphan)?

• Not determinable.

What FDA-listed waivers or exclusivity blocks generic entry?

• Not determinable.

When does Elite Pharm Solution lose exclusivity and face generic or biosimilar entry risk?

Answer: Not determinable from the information provided.

What are the expiration timelines by active ingredient?

• Not determinable.

What is the Paragraph IV risk profile?

• Not determinable.

What triggers 180-day exclusivity for challengers?

• Not determinable.

Which companies are challenging Elite Pharm Solution’s IP through Paragraph IV filings?

Answer: Not determinable from the information provided.

What is the filing-to-suit timeline for relevant ANDA cases?

• Not determinable.

How many cases target formulation versus method-of-use patents?

• Not determinable.

What settlement patterns affect launch timing?

• Not determinable.

What formulations are protected by Elite Pharm Solution patents and how does that affect generic design-around?

Answer: Not determinable from the information provided.

Which dosage forms have the highest formulation-IP density?

• Not determinable.

What delivery-system patents (extended release, inhalation, transdermal, ophthalmic) exist?

• Not determinable.

What manufacturing or process patents constrain contract manufacturing?

• Not determinable.

What patent litigation affects Elite Pharm Solution and its competitive set?

Answer: Not determinable from the information provided.

Which courts and case numbers matter?

• Not determinable.

What is the current status (dismissed, stayed, trial, appeal)?

• Not determinable.

Do preliminary injunctions or stipulations change near-term entry risk?

• Not determinable.

How does Elite Pharm Solution compare with its closest branded and generic competitors?

Answer: Not determinable from the information provided.

Side-by-side product and exclusivity comparison

• Not determinable.

Pricing or contracting leverage versus peers

• Not determinable.

Manufacturing scalability and supply risk versus competitors

• Not determinable.

What biosimilar or interchangeability risk applies to Elite Pharm Solution biologics (if any)?

Answer: Not determinable from the information provided.

What is the biologic target and whether a biosimilar has launched?

• Not determinable.

What patent mechanisms apply (reference product exclusivity, BLA pathway, patent thicket)?

• Not determinable.

What is the biosimilar launch runway (12-year reference product exclusivity, BPCIA timelines)?

• Not determinable.

What licensing deals or collaborations shape Elite Pharm Solution’s competitive advantage?

Answer: Not determinable from the information provided.

What licensed products expand the pipeline or shore up revenue?

• Not determinable.

What cross-licenses reduce litigation exposure?

• Not determinable.

What “inbound” or “outbound” deals affect manufacturing and commercialization rights?

• Not determinable.

What generic entry scenarios exist for Elite Pharm Solution’s products?

Answer: Not determinable from the information provided.

Scenario A: Launch upon exclusivity expiry without patent challenge

• Not determinable.

Scenario B: Paragraph IV challenge with potential 180-day exclusivity

• Not determinable.

Scenario C: Design-around constrained by formulation or method patents

• Not determinable.

Scenario D: Practical launch blocked by manufacturing or regulatory data exclusivities

• Not determinable.

Key takeaways

• A complete competitive landscape for “Elite Pharm Solution” requires the specific active ingredients, dosage forms, and FDA/Orange Book identifiers linked to the correct legal entity.
• A patent-and-litigation map by jurisdiction is necessary to quantify generic and biosimilar risk and define launch barriers.
• Market-position conclusions depend on product-level revenue exposure and channel mix, which are not provided.

FAQs

1. How do you identify the correct FDA Orange Book listing for Elite Pharm Solution’s products?
   Not determinable from the information provided.

2. Which patents typically block ANDA approval when exclusivity expires for the reference product?
   Not determinable from the information provided.

3. What settlement terms most often delay or accelerate generic launch timelines in Hatch-Waxman cases?
   Not determinable from the information provided.

4. How do formulation patents (extended release, polymorphs, salts, particle size) change generic design-around strategies?
   Not determinable from the information provided.

5. What BPCIA milestones control biosimilar launch risk when a reference product has active patent coverage?
   Not determinable from the information provided.

References (APA)

1. None cited.